3BBLACKBIO1,440.00

3B Blackbio Dx Limited

· Pharma & Health
₹ CrorePeersHEALTHXSURAKSHAKRSNAANEPHROPLUS
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation0.90.9
Changes in Working Capital
+ Inventories-0.3-0.2
+ Trade Receivables — Current-6.0-0.5
+ Trade Payables — Current4.41.2
Cash from Operating Activities
Profit Before Tax (per I/S)46.463.9
Cash from Operations (pre-tax)39.359.3
Cash from Operating Activities28.544.5
Cash from Investing Activities
Cash from Investing Activities-20.3-33.6
Cash from Financing Activities
+ Interest Paid0.10.1
Cash from Financing Activities-3.6-3.1
Net Changes in Cash4.57.8
Reference Items
EBITDA35.149.9
EBITDA Margin %49.6455.07
Free Cash Flow (CFO − Capex)28.544.5
Free Cash Flow to Equity44.0
Cash Flow to Net Income0.830.93
Cash Paid for Interest0.10.1
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY25 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 85%.